<?xml version="1.0" encoding="UTF-8"?>
<p>Until week 6, the high‐dose patient group exhibited an increased muscle force recovery (although not significant) that decreased thereafter; the low‐dose group showed a slower but persistent increase and the best performance at week 26 (
 <italic>Figure</italic>
 <xref rid="jcsm12316-fig-0003" ref-type="fig">3</xref>). Interestingly, only high‐dose patients developed significant signs of unspecific immune stimulation at week 6 corresponding to their poorer performance in terms of efficacy parameters after this time point. 
 <italic>Figure</italic>
 <xref rid="jcsm12316-fig-0006" ref-type="fig">6</xref>E–6F shows rising plasma IL‐10 and bystander T‐cell activation for this group.
</p>
